These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20856209)

  • 1. Focal segmental glomerulosclerosis: a very unusual complication of allogeneic hematopoietic cell transplantation (HCT).
    Lopes JA; Martins C; Jorge S; Melo MJ; Resina C; Moreno R; do Carmo JA
    Bone Marrow Transplant; 2011 Jul; 46(7):1019-20. PubMed ID: 20856209
    [No Abstract]   [Full Text] [Related]  

  • 2. Focal nodular hyperplasia in pediatric allogeneic hematopoietic cell transplant: case series.
    Anderson L; Gregg D; Margolis D; Casper J; Talano J
    Bone Marrow Transplant; 2010 Aug; 45(8):1357-9. PubMed ID: 20140023
    [No Abstract]   [Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucous membrane pemphigoid following reduced intensity conditioning allogeneic haematopoietic SCT for biphenotypic leukaemia.
    Mahmood S; Lim ZY; Benton E; du Vivier A; Bhogal B; Mufti GJ; Pagliuca A
    Bone Marrow Transplant; 2010 Jan; 45(1):195-6. PubMed ID: 19430504
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.
    Willems E; Baron F; Seidel L; Frère P; Fillet G; Beguin Y
    Bone Marrow Transplant; 2010 Apr; 45(4):689-93. PubMed ID: 19718063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BK virus nephropathy after allogeneic stem cell transplantation: a case report and literature review.
    Lekakis LJ; Macrinici V; Baraboutis IG; Mitchell B; Howard DS
    Am J Hematol; 2009 Apr; 84(4):243-6. PubMed ID: 19208419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory bowel disease after allogeneic stem cell transplantation.
    Boussen I; Sokol H; Aractingi S; Georges O; Hoyeau-Idrissi N; Hugot JP; Mohty M; Rubio MT
    Bone Marrow Transplant; 2015 Oct; 50(10):1365-6. PubMed ID: 26052914
    [No Abstract]   [Full Text] [Related]  

  • 8. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute fulminant myocarditis after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning for acute myelogenous leukemia.
    Nakaseko C; Sakaida E; Ohwada C; Ozawa S; Takeuchi M; Shimizu N; Cho R; Yokota A; Saito Y; Nishimura M
    Ann Hematol; 2007 Jan; 86(1):67-9. PubMed ID: 17021838
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe metabolic abnormalities after allogeneic hematopoietic cell transplantation.
    Lee JH; Choi SJ; Lee JH; Kim SE; Seol M; Lee YS; Lee JS; Kim WK; Lee KH
    Bone Marrow Transplant; 2005 Jan; 35(1):63-9. PubMed ID: 15502852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation.
    Dvorak CC; Steinbach WJ; Brown JM; Agarwal R
    Bone Marrow Transplant; 2005 Oct; 36(7):621-9. PubMed ID: 16044133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
    Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
    Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating endothelial cell enumeration demonstrates prolonged endothelial damage in recipients of myeloablative allogeneic stem cell transplantation.
    Beije N; Versluis J; Kraan J; Gratama JW; Sleijfer S; Cornelissen JJ
    Haematologica; 2015 Jun; 100(6):e246-9. PubMed ID: 25710454
    [No Abstract]   [Full Text] [Related]  

  • 15. Focal segmental glomerulosclerosis in fifty-nine renal allografts from a single centre; analysis of risk factors for recurrence.
    Cameron JS; Senguttuvan P; Hartley B; Rigden SP; Chantler C; Koffman G; Williams DG; Ogg CS
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2117-8. PubMed ID: 2652683
    [No Abstract]   [Full Text] [Related]  

  • 16. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Willems E; Humblet-Baron S; Dengis O; Seidel L; Beguin Y; Baron F
    Bone Marrow Transplant; 2010 Sep; 45(9):1442-8. PubMed ID: 20062090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for acute graft-versus-host disease.
    Khaled Y; Reddy P; Krijanovski O
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):219-32. PubMed ID: 19519285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation.
    Yao S; Smiley SL; West K; Lamonica D; Battiwalla M; McCarthy PL; Hahn T
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1130-7. PubMed ID: 20188201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.